药物治疗慢性粒细胞白血病的研究进展

Research progress of medical therapies for chronic myeloid leukemia

慢性粒细胞白血病(chronic myelocytic leukemia,CML)是一种以粒系细胞增生为主要特征的多能干细胞疾病。Ph染色体出现在95%的CML患者中,该染色体上表达的BCR-ABL融合蛋白具有持续的酪氨酸激酶活性,它在细胞信号转导过程中不断磷酸化和活化下游底物,使细胞不断增殖和迁移,导致CML的发生。近年,人们一直在尝试各种方法治疗CML,包括开发化学药物,中药提取物,以及针对BCR-ABL酪氨酸激酶设计合成的抑制剂等。经临床验证,这些药物已经取得显著的疗效。本文即为治疗慢性粒细胞白血病的药物的研究进展作一综述。

Chronic myeloid leukemia（ CML） is a pluripotent stem cell disease characterized by the proliferation of myeloid cell. Ph chromosome has been found in 95% of CML patients. BCR-ABL fusion protein expressing on Ph chromosome displayed constitutive tyrosine kinase activity. The fusion protein could phosphorylate and activate downstream substrates continually in the process of cell signal transduction,and then cells proliferate and migrate constantly,resulting the occurrence of CML. In recent years,people have been tried various methods to cure CML,which included developing some chemotherapy drugs and herbal extracts,as well as designing and synthesizing the inhibitors targeting BCR-ABL tyrosine kinase. Clinical studies showed that these drugs have been achieved remarkable effects. This paple aimed to review for drugs treated in CML.